Arix Bioscience Stock

Arix Bioscience Equity

Delisted·Feb 9, 2024

The The Equity of Arix Bioscience (ARIX.L) as of Aug 19, 2026 is 225.91 M GBP. In the previous year, The Equity was 255.40 M GBP — a change of -11.55% (lower).

Equity

225.91 MGBP

YoY

-11.55%

Last updated:

In 2026, Arix Bioscience's equity was 225.91 M GBP, a -11.55% increase from the 255.40 M GBP equity in the previous year.

Access this data via the Eulerpool API

Arix Bioscience Stock analysis

What does Arix Bioscience do? Arix Bioscience PLC is a leading investment and management provider in the biotech industry. The company is focused on identifying, investing in, and growing emerging companies to develop groundbreaking therapies for patients worldwide. The firm was founded in 2016 in London, United Kingdom, and has since focused on collaborating with emerging biotech companies. Arix is now one of the fastest-growing biotech companies in the region, with locations in London, New York, and Zug, Switzerland. Arix Bioscience's business model is based on investing in young biotechnology companies and supporting their growth. The goal is to develop new drugs and therapies by driving innovation in the biotech industry, ultimately benefiting patients worldwide, including those with rare or incurable diseases. To achieve these goals, Arix Bioscience operates in three divisions: Investment, Management, and Discovery. The Investment division actively invests in young biotech companies that aim to develop and commercialize groundbreaking therapies and new diagnostic methods. The company not only provides financial resources but also has extensive experience in the biotech industry and a variety of contacts to offer advisory support when needed. The Management division focuses on effectively managing investments in young biotech companies to fully unleash their growth potential. Arix Bioscience assists these companies, for example, in finding suitable candidates for leadership positions, planning clinical trials, or exploring new markets. The Discovery division specifically targets the discovery and development of new therapies and medications. The company works directly with biotech startups to create a comprehensive value chain that spans from the discovery and exploration of drug molecules to clinical validation. To achieve these goals, Arix Bioscience collaborates closely with leading biotech startups and research institutions worldwide. The company has extensive relationships and networks in the biotech industry, allowing it to optimize the support it provides to its portfolios. Among the products provided by Arix Bioscience is a portfolio of drugs and therapies developed by the biotech companies in which Arix has invested. These portfolios include successful products such as the CD19 CAR-T therapy developed by Autolus Therapeutics, which is used in cancer treatment. Another example is MiroBio, a company in which Arix Bioscience has invested to develop a new medication for autoimmune diseases. Here too, Arix Bioscience has utilized its investment and management expertise to successfully support the company's growth. Overall, Arix Bioscience is a company with a clear focus on innovation and growth in the biotech industry. The company actively invests in emerging biotech startups and provides targeted management and comprehensive support to lead them to great successes. With its extensive experience, Arix Bioscience has become an important player in the development of new therapies and medications. Arix Bioscience is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Arix Bioscience's Equity

Arix Bioscience's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Arix Bioscience's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Arix Bioscience's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Arix Bioscience's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Arix Bioscience’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Arix Bioscience stock

The Equity of Arix Bioscience is 225.91 M GBP in 2026.

The Equity of Arix Bioscience changed from 255.40 M GBP to 225.91 M GBP, representing a -11.55% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Arix Bioscience since 2006 – with annual values, charts, and detailed analysis.

The Equity's GBP is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Arix Bioscience historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Arix Bioscience

All Key Metrics — Arix Bioscience